Exhibit 99.1

        FDA Approves Mediscience Optical Biopsy Device multi-center pilot
               study for molecular cancer detection of the cervix

CHERRY HILL, N.J.--(BUSINESS WIRE)--April 3, 2006 Mediscience Technology, Corp.
(OTCBB:MDSC.OB) announced today: The Food and Drug Administration on March 29,
2006 approved as a "Non-significant risk device study the Company's multi-center
pilot study to establish the safety and parameters of efficacy of its
proprietary Optical Biopsy Device (CD-R) for cancer detection of the cervix
preliminary to a pivotal study" expected to bring this molecular algorithmic
specific technology to market.

Dr Robert Schiff of Schiff & Company/ Regulatory Affairs advised "The FDA has
notified Mediscience that the device (CD-R) is a non-significant risk device. We
can therefore commence the Pilot study at any time observing the regulations
governing patient consent and institutional IRB approval. The FDA has also given
us comments and suggestions which will assist Mediscience in its clinical
studies."

Peter Katevatis Chairman/ CEO "The main objectives of this pilot study are to
determine efficacy; the clinical sensitivity and clinical specificity (ability
for the device to distinguish between tissues that are normal, benign,
precancerous low grade, precancerous high grade, CIS and cancer) by comparing
the device real-time results to the PAP test and biopsy; and assess any adverse
events based on Good Clinical Practices. Frequency, type and intensity of
clinical adverse events will also be evaluated. Assuming the results of this
initial efficacy and safety study are satisfactory, in the detection of cervical
cancer precursors i.e. (pre-cancerous cells), indications of possible cancer
development the Company will continue into its pivotal study where the principal
endpoint will be proof of effectiveness in a statistically significant sample of
subjects.

Dr. Robert Alfano (pioneer in optical biopsy, co-founder and advisor to
Mediscience Technology and President of Alfanix LTD) " This FDA approval
advances Mediscience to the next level towards commercialization and is a major
step in advancing diagnostic medicine using fluorescence light. Alfanix plans to
help Mediscience with it's CD-R platform technology in the medical cancer areas
and possibly expanding the market into Latin America."

Mediscience Technology Corporation is engaged in the design and development of
fluorescence-based optical biopsy platform system that uses the properties of
light and its molecular interaction with tissue to aid in the diagnosis of
physiological change and cancer.

The Mediscience IP technology platform is based on imaging native fluorescence
from the surface of an optically excited tissue and offers paradigm shift
potential as a noninvasive, in-vivo cancer diagnostic because of the unique
ability to detect/distinguish abnormalities in molecular tissue composition
and/or structure. Further, the development of a Mediscience cost effective, high
resolution commercial imaging system for real-time

                                                                               4


in-vivo diagnostics has the potential to vastly improve upon current standards
of diagnostic sensitivity and specificity. (e.g. Cervical cancer a highly
preventable cancer with early detection and removal of pre-cancerous cervical
lesions)

About Mediscience Technology

Mediscience Technology Corporation and its New York subsidiary, Medi-photonics
Development Company LLC, are engaged in the design, development and
commercialization of medical devices that detect cancer and physiological change
using frequencies of light that are emitted, scattered and absorbed to
distinguish malignant, Pre-cancerous or benign tissues from normal tissues.
Mediscience's exclusive protected noninvasive technology combines the advantages
of real-time results with enhanced diagnostic sensitivity and specificity
compared with other methods of cancer detection.

www.infotonics.org/ResearchProjects/CompactPhotonicExplorers.asp
www.cunyphotonics.com
www.MEDISCIENCETECH.com
Mediscience 8-K filing dated April 4, 2006
New England Journal of Medicine 7-29-04 (capsule endoscopic technology)
CITIGROUP/Smith Barney Analyst Report 10-1-2004 by Peter Bye. Page
20 (Mediscience/Infotonics)
Alfanix LTD Dr. Robert Alfano 917 969 2209 web: info@alfanix.com

                                 INVESTOR NOTICE

      Certain of the matters discussed in this announcement contain
forward-looking statements that involve material risks to and uncertainties in
the parties/company's business that may cause actual results to differ
materially from those anticipated by the statements made herein. Such risks and
uncertainties include among other things, the availability of financing, the
parties/ company's ability to implement its long-range business plan for the
joint or independent development of various applications of its technology/ IP;
the company's ability to enter into future agreements with any necessary
marketing and/or distribution partners; the impact of competition, the obtaining
and maintenance of any necessary US regulatory i.e. FDA clearances applicable to
applications of the company's technology; and management of growth and other
risked and uncertainties that may be detailed from time to time in the
parties/company's reports filed with the Securities and Exchange Commission.
This disclosure is intended to satisfy: SEC Section 6, 6.01 Regulation FD,
disclosure and Section 7 and 7.0 as well as all applicable and presently
effective Sarbanes-Oxley disclosure requirements under Regulation G.

      CONTACT: Mediscience ---Peter Katevatis Chairman/CEO 215 485 0362 or
      metpk@aol.com Dr. Robert Alfano 917 969 2209 web: info@alfanix.com


                                                                               5